Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. RNAi therapeutic development
3. RNAi cellular activity
4. In vivo siRNA delivery is the key
5. Clinically-viable siRNA deliveries
6. Intra-tumoral siRNA delivery
7. Gene silencing in tumor
8. Raf-1 siRNA inhibits tumor growth
9. siRNA-mediated validation in vivo
10. Cancer target validation
11. RNAi effect in mouse brain
12. RNAi effects in mouse CIA model
13. Ocular siRNA delivery subconjunctival
14. Ocular siRNA delivery: intravitreus
15. Intra-tracheal siRNA delivery
16. Primate study design
17. Relief from SCV-induced fever
18. Minimized lung damages
19. Protect monkey lung from infection
20. Challenges to siRNA systemic delivery
21. Systemic delivery technology
22. Targeted nanoparticle siRNA delivery
23. Self assembled nanoparticle
24. Integrin alfa-v-beta-3 is validated target
25. Dual-targeted therapeutic approach
26. Neovasculature targeting siRNA
27. Multi-targeted anti-angiogenesis
28. Systemic siRNA delivery to eyes
29. Efficient targeted systemic delivery
30. Neuroblastoma treatment
31. Tumor neovasculature inhibition
32. siRNA/atelocollagen anti-tumor efficacy
33. Transferrin-mediated systemic delivery
34. Antibody-mediated tumor targeting
35. Targeted anti-HBV activity
36. RNAi effect of chol-siRNA
37. PEI-mediated siRNA lung targeting
38. Conclusion: therapeutic delivery

Topics Covered

• RNAi therapeutics development
• RNAi cellular activity
• In vivo siRNA delivery is key
• Clinically viable siRNA deliveries
• Local delivery of siRNA
• Gene silencing in tumors
• Cancer target validation in vivo
• RNAi effects in mouse brain, joints, eyes and lungs
• siRNA therapeutics in primate models
• Challenges to siRNA systemic delivery
• Systemic delivery technology
• Targeted nanoparticle siRNA delivery
• Self assembled nanoparticle
• Integrin av-beta is a validated target
• Dual-targeted therapeutic approach
• Neovasculature targeting siRNA
• Multi-targeted anti-angiogenesis
• Efficient targeted systemic delivery
• Systemic siRNA delivery to eyes
• Systemic siRNA delivery for neuroblastoma treatment
• Tumor neovasculature inhibition
• siRNA/Atelocollagen anti-tumor efficacy
• Transferrin-mediated systemic delivery
• Antibody-mediated tumor targeting
• Targeted anti-HBV activity
• RNAi effect of chol-siRNA
• PEI-mediated siRNA lung targeting
• Clinicallyviable delivery is the key for successful siRNA therapeutics

Links

Series:

• RNA Interference

Categories:

• Cell Biology
• Genetics & Epigenetics
• Pharmaceutical Sciences

Talk Citation

Publication History

• Published on October 1, 2007
• Archived on February 25, 2021

Financial Disclosures

• Dr. Patrick Lu has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.